Helsinki Biobank and Fimmic Introduce a Unique One Access Service for Biomedical Research
Tissue sample collections and digital services with deep learning -based image analysis solutions now available as a combined service
Helsinki Biobank and medical AI software company Fimmic announce a collaboration by presenting a unique one access service concept. The new service combines Helsinki Biobank´s large collection of pathology samples and world-class digital services with state-of-the art deep learning AI -based image analysis solutions from Fimmic.
Faron Pharmaceuticals Admission to AIM and first day of dealings £10 million fundraise to progress Phase III clinical trial
Faron Pharmaceuticals Oy ("Faron”), the clinical stage biopharmaceutical company, is pleased to announce the commencement of dealings in its Ordinary Shares on the AIM market of the London Stock Exchange with effect from 8.00 a.m. today under the ticker FARN and the ISIN number FI4000153309. This follows a successful placing and subscription for 3,846,154 new Ordinary Shares, raising £10.0 million at a price of 260p per ordinary share (the “Fundraising”).
Faron Enters Agreement with Selexis SA to Progress Development of Novel Cancer Immunotherapy Clevegen
Faron Pharmaceuticals Oy (”Faron”), the clinical stage biopharmaceutical company, announced today it has entered into an agreement with Swiss-based Selexis SA. Under the agreement, Faron will have access to the Selexis SUREtechnology Platform™ and SURE CHO-M Cell Line™ for the production of high-expressing and stable clonal cell lines for use in the development and production of Clevegen, its novel cancer immunotherapy antibody.